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Abstract
Infected deep vein thrombophlebitis (i-DVT) in people who inject drugs (PWID) is a clinically challenging but poorly char-
acterised disease. We undertook a retrospective observational study of 70 PWID presenting acutely with i-DVT to improve 
the clinical and microbiological characterisation of this disease. i-DVT was frequently associated with bacteraemia (59.1% 
patients with blood cultures obtained), groin abscesses (in 34.3%; of which 54.2% required surgical drainage), and septic pul-
monary emboli (38.6%) requiring anticoagulation. Network analysis identified a cluster of patients presenting with respiratory 
symptoms but lacking typical DVT symptoms, more likely to have septic pulmonary emboli. A microbiologic diagnosis was 
frequently achieved (70%). Causative pathogens were predominantly gram-positive (S. aureus and streptococci, especially 
anginosus group), whereas gram-negative pathogens were identified very infrequently (in 6.1% of microbiological diagno-
ses). This suggests routine empiric therapy against gram-negative bacteria, though commonly administered, is not required. 
High rates of clinical cure (88.6%) were observed despite the complex nature of infections and independently of the highly 
variable intravenous and total antimicrobial durations received. There exists a rationale to devise pragmatic approaches to 
implement novel individualised treatment plans utilising oral antimicrobial therapy for i-DVT. Despite frequent healthcare 
interactions, opportunities to address HCV treatment and opioid substitution therapy were frequently missed during these 
acute admissions.
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Introduction
People who inject drugs (PWID) are at increased risk of 
bacterial disease complicating injections, including cel-
lulitis, abscesses and infective endocarditis (IE). Infected 
deep vein thrombophlebitis (i-DVT) is estimated to account 
for up to 11% of infectious complications amongst hospi-
talised PWID, based on a single-centre Swiss retrospective 
observational study [1]. I-DVT is a clinically challenging 
entity but poorly characterised. Optimal management is not 
defined, particularly in comparison to IE in PWID [1–3]. In 
general, PWID are a therapeutically disenfranchised group, 
often excluded from potentially relevant clinical trials, con-
tributing to a lack of data to guide therapeutic decisions. To 
improve the clinical characterisation of this entity, we under-
took a retrospective observational study of PWID presenting 
acutely with i-DVT.
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Cases were defined as (1) adults currently injecting drugs 
intravenously, presenting with (2) radiologically confirmed 
upper or lower limb DVT (excluding isolated superficial 
thrombophlebitis) with (3) evidence of infection, either 
(i) radiological or intra-operative (inflammatory vessel 
changes associated with thrombus, gas in thrombus, ves-
sel with thrombus contiguous with abscess) or (ii) micro-
biological (bacteraemia or culture-positive intra-operative 
thrombus sample). Electronic patient records and Infec-
tious Disease consultation records were searched for the 
terms “DVT”, “PWID” and “IVDU” for patients admit-
ted to infectious disease, vascular surgery or critical care 
wards from January 2017–December 2018 inclusive, 
identifying 2957 acute admissions, 70 of which met the 
case definition and had available records. This work was 
approved by the NHS Lothian Infection Service Quality 
Improvement Team.
Analysis
Microbiological cure was defined as a negative blood 
culture (BC) following a positive BC. Clinical cure was 
defined as no re-admission due to the same infection 
within one year of discharge. Symptom clusters were 
identified by network analysis using the Markov Cluster-
ing Algorithm (Graphia, version 2.0 [4]). Groups were 
compared using unpaired t-tests, Mann–Whitney tests or 
Fisher’s exact tests as appropriate.
Results
Cohort characteristics
Patients were predominantly male (46/70; 65.7%) with 
a median age of 37 years (Table 1, Table S1). Prior to 
admission 10/70 (14.3%) patients had no fixed abode 
and 10/70 (14.3%) resided in non-permanent accommo-
dation. All patients injected heroin with 41/70 (58.6%) 
using additional substances, most frequently cocaine and/
or benzodiazepines (Table 1; Figure S1). Active hepatitis 
C was present in 22/70 (31.4%), with 7 of these being 
new diagnoses during the index hospitalisation. Thirty-
six patients (51.4%) had previously been hospitalised due 
to complications of injection drug use (median of 1, IQR 
1–3, range 1–15), commencing a median of 33 months 
Table 1  Cohort characteristics
Data shown as n (%) unless otherwise stated
a Denominator = 70 unless otherwise stated
b Data available for n = 68
c Blood cultures obtained in n = 66
IQR interquartile range, HIV human immunodeficiency virus, HBV 






 Age, median (IQR) years 37 (32–41)
 Temporary accommodation or no fixed abode 20 (28.6)
Substance use
 Alcohol excess 10 (14.3)
 Heroin only 29 (41.4)
  + Cocaine 26 (37.1)
  + Benzodiazepines 26 (37.1)
  + Cannabis 9 (12.9)
  + New psychoactive substance 5 (7.1)
  + Others 6 (8.6)
Blood borne viruses
 HIV positive 0
 Active HBV 2 (2.9)
 Active HCV 22 (31.4)
 Prior cleared HCV 15 (21.4)
Presentation
 Symptom duration prior to admission, median (IQR) days 4.5 (3–7)
 Vital signs, median (IQR)
  Pulse, beats/min 102 (85–118)
  Systolic BP, mmHg 113 (90–123)
   SpO2, % 97 (95–99)
  Temperature, °C 38.4 (37.5–39)
  Respiratory rate, breaths/min 17 (16–19)
Antimicrobial durations,
median (IQR)  daysb
 Intravenous 18 (7–29)
 Oral follow-on (n = 54) 14 (14–27)
 Combined 29 (28–43)
Surgical intervention
 Abscess drainage 13 (18.6)
 Pseudoaneurysm ligation 4 (5.7)
Complications
 Bacteraemia 39/66 (59.1)c
 Septic pulmonary emboli 27 (38.6)
 Groin abscess 24 (34.3)
 Arterial involvement 8 (11.4)
 Pseudoaneurysm 6 (8.6)
 Splenic emboli 3 (4.3)
 Infective endocarditis 3 (4.3)
Outcomes
 Clinical cure 62 (88.6)
 Microbiological cure 38/39 (97.4)
 Substance-use related admission in year after discharge 32 (45.7)
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(IQR 20–64.75) previously, commonly due to cellulitis 
(n = 28) and/or deep vein thrombosis/pulmonary embolism 
(DVT/PE; n = 19).
Presenting features
Network analysis identified distinct symptom clusters. Com-
binations of leg pain with/without swelling and fever were 
the most common presenting symptoms, but one cluster of 
patients presented predominantly with fever and respira-
tory symptoms (≥ 1 of cough, dyspnoea or pleuritic chest 
pain; Table S1, Figure S2). Laboratory evidence of systemic 
inflammation was common (median CRP 220 mg/L [IQR 
175–292]; median neutrophils 9.8 ×  109/L [6.9–13.9]) but 
overt sepsis (qSOFA ≥2) was uncommon (7/60; 11.7%) 
(Table 1, Figure S3). Thirteen patients were admitted to the 
intensive care unit. Radiologic confirmation of DVT was by 
US (46/49; 93.9%) and/or CT (36/55; 65.6%), identifying 
thrombi most commonly in the common femoral (n = 29), 
external iliac (n = 17) or common iliac (n = 14) veins. Abnor-
malities were present in 21/61 (34.4%) chest x-rays (cavitat-
ing pneumonia in four). Thoracic CT (pulmonary angiogram 
24; venous contrast 13) identified definite emboli in 6/37 
(16.2%) and cavitation in 23/37 (62.2%) patients who under-
went imaging; more often in the respiratory symptom cluster.
Microbiological findings
Bacteraemia was identified in 39/66 (59.1%) patients with 
BC obtained at presentation (9 polymicrobial). Bacterae-
mic patients had a median of 1 positive BC per organism 
(range 1–3). Seven patients had > 1 positive BC; in all cases 
Staphylococcus aureus. Intra-operative samples were cul-
ture-positive from 16/19 (84.2%) patients where obtained. 
Considering BC and intra-operative samples together, 
a microbiological diagnosis was made in 49/70 (70%) 
patients; monomicrobial in 32/49 (65.3%). Most monomi-
crobial infections were due to S. aureus (21/32, 65.6%). S. 
aureus, streptococci (especially anginosus group) and anaer-
obes were the most commonly identified pathogens overall 
(Table S2). Gram-negative organisms were infrequently 
identified (3 patients).
Antimicrobial therapy
All patients (n = 68 data available) were initially treated 
with intravenous antimicrobials continuing for a median of 
18 days (IQR 7–29), with oral follow-on therapy in 54/68 
(79.4%) patients, prescribed for a median of 14 days (IQR 
14–27), resulting in a median total duration of 29 days (IQR 
28–43) but with substantial variation (Fig. 1A). The median 
inpatient stay was 24 days (IQR 12–29). Adherence to oral 
antimicrobial therapy after discharge is unknown, thus these 
data are the upper bound to oral and total durations. An 
enforced early IV-to-oral switch occurred in three patients 
due to intravenous access difficulties and in eight due to 
discharge against medical advice.
Initial empiric antimicrobial therapy favoured S. aureus 
coverage, with 65/69 (94.2%) patients receiving agents 
with activity against gram-positive pathogens including S. 
aureus (Fig. 1C; Table S3). In 40/69 (58%) patients, initial 
empiric therapy also included gram-negative and anaerobic 
coverage. Total antimicrobial days were summed and the 
proportion accounted for by each ‘spectrum’ was derived 
(Table S4). Specific anti-staphylococcal gram-positive ther-
apy accounted for 42.4% of antimicrobial days, followed by 
anaerobic therapy (24.9%), broad-spectrum therapy (13.0%), 
narrow-spectrum gram-positive therapy (9.9%) and gram-
negative therapy (8.8%).
Other management
Peripherally inserted central catheters or midlines, inserted 
by an anaesthetist or radiologist (excluding central venous 
access for vasopressors), were required for intravenous access 
in 32/70 (45.7%) patients. Surgical intervention was required 
in 22/70 (31.4%) patients, most commonly for abscess drain-
age (n = 13) or pseudoaneurysm ligation (n = 4). Therapeutic 
anticoagulation was initiated with subcutaneous low molecu-
lar weight heparin (LMWH) for most patients (57/70; 81.4%) 
or LMWH followed by a direct-acting oral anticoagulant 
(DOAC; n = 7) or DOAC alone (n = 1). Four patients were not 
anticoagulated and one was already taking therapeutic anti-
coagulation. The majority of patients received long-term opi-
oid substitution therapy, however, 14/70 (20%) patients were 
discharged without a treatment plan (Fig. 1D). Sixteen (of 
22; 72.7%) patients with active HCV infection were offered 
outpatient treatment; only six ultimately received treatment. 
In five patients active HCV infection was not addressed. Data 
was unavailable for one patient with active HCV.
Complications
Septic pulmonary emboli (n = 27 [38.6%]; either definite 
emboli or cavitation) and groin abscesses (n = 24, [34.3%]; 
of which 13 underwent drainage [54.2%]) were the most 
common complications. Adjacent arterial involvement 
(n = 8; 11.4%) and pseudoaneurysms (n = 6; 8.6%) were less 
common. Other metastatic complications included: splenic 
emboli (n = 3; 4.3%), IE (n = 3 [4.3%]; 50/66 underwent 
echocardiography), vertebral osteomyelitis (n = 1; 1.4%), 
septic arthritis (metatarsophalangeal joint, n = 1; 1.4%), pul-
monary artery pseudoaneurysm requiring surgical interven-
tion (n = 1; 1.4%), right ventricle thrombus containing an 
embolised needle tip (n = 1; 1.4%) and necrotising fasciitis 
of the groin and abdominal wall (n = 1; 1.4%).
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Outcomes
Amongst patients with data available, microbiological cure was 
achieved in 38/39 (97.4%) cases. Clinical cure was achieved in 
62/70 (88.6%) cases and there were no deaths during the index 
admission. Clinical failure leading to re-admission occurred 
an average of 17 days after discharge (SD ± 9, range 5–26). 
32 (45.7%) patients had a further admission within one year 
due to other complications of injection drug use. Bacteraemia, 
S. aureus disease, septic shock, qSOFA/SIRS, inflammatory 
markers, metastatic infection and local abscess were not asso-
ciated with clinical failure on univariable analyses. Duration 
of intravenous, inpatient or total antimicrobials was also not 
associated with outcome (Table S5, Fig. 1B).
Discussion
i-DVT in PWID was frequently associated with bacterae-
mia, groin abscesses and septic pulmonary emboli. Patients 
often received lengthy antimicrobial courses associated 
with extended hospitalisations. Despite the complex nature 
of infections, outcomes were surprisingly good, with clini-
cal cure in 88.6% of patients. Moreover, cure occurred 
independent of highly variable durations of antimicrobial 
therapy. Patient characteristics and outcomes reported here 
are similar to other smaller studies (Table S6) [1, 5, 6]. In 
a North American cohort of PWID with invasive bacterial 
infections (predominantly IE and bone/joint infections), 
outcomes were similar for patients who completed a pro-
longed intravenous antimicrobial course and those who 
required partial oral therapy (and superior to those who did 
not complete intravenous therapy nor receive partial oral 
therapy) [7]. Combined with data supporting partial oral 
therapy for the treatment of IE and osteomyelitis (in studies 
excluding PWID [8, 9]), we contend there exists a rationale 
to devise pragmatic approaches to implement novel indi-
vidualised treatment plans utilising oral antimicrobial ther-
apy for i-DVT. A microbiologic diagnosis was frequently 
achieved (49/70 patients). S. aureus, streptococci and anaer-
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Fig. 1  Inpatient management. A Duration of inpatient stay and anti-
microbial therapy (intravenous [IV], oral, and total [IV and oral com-
bined]). B Comparison of the duration of intravenous, inpatient and 
total antimicrobial therapy between patients with and without clinical 
cure. Data available for 68 patients. Groups compared by Mann Whit-
ney test. Solid line within violin plot shows median and dotted lines 
show first and third quartiles. C Initial spectrum of empiric antimi-
crobial therapy. Definitions of different spectra are presented in Sup-
plementary Table 3. D Opioid substitution therapy
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gram-negative pathogens were identified very infrequently 
(in 3/49 patients with a microbiological diagnosis). Consid-
ering the rarity of identifying gram-negative pathogens, we 
propose that routine use of broad spectrum/gram-negative 
therapy empirically is not required.
Although treatment failure of the index infection was 
uncommon, readmissions within one year with other com-
plications of injection drug use occurred in almost half 
the cohort (45.7%), justifying intensification of efforts to 
address causation. Fourteen patients (20%) were discharged 
without addressing opioid substitution therapy. Active HCV 
was common (31.4%) but only a minority were successfully 
engaged in treatment. There was minimal documentation 
regarding harm reduction measures. In Scotland, drug-
related acute admissions are increasing steadily with 10,509 
admissions in 2017–18 (199 stays/100,000 population), rep-
resenting 7,986 distinct patients of which 54% had not been 
admitted before[10].
The generalisability of these results is limited by the 
single-centre design. Our ability to identify predictors of 
treatment failure was limited by the low event rate. Patients 
re-admitted to hospitals outwith the geographic area of the 
study would not have been identified so the figures presented 
for clinical cure represent an upper bound (i.e. we may have 
missed cases of clinical failure); however local experience 
suggests this is unlikely to have been a frequent event.
This report addresses a deficit in the clinical and micro-
biological characterisation of i-DVT in PWID, providing a 
basis for reformed antimicrobial approaches. Despite fre-
quent interactions and prolonged hospital stays, we also 
identify missed opportunities to address causal factors and 
more specifically to target the reservoir of active HCV in 
PWID. PWID presenting acutely with i-DVT represent a 
high-risk group in need of an integrated, holistic approach to 
management and efforts to facilitate healthcare engagement.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s15010- 021- 01725-3.
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